如何看待洋地黄类正性肌力药在急性心力衰竭治疗中的作用及价值

doi:10.3969/j.issn.1002-1949.2018.01.004

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (434 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要心力衰竭（heart failure，简称心衰）是由于心脏结构或功能异常导致心室充盈或射血能力受损的一组临床综合征，其病理生理学特征为肺淤血和（或）体循环淤血以及组织器官低灌注。急性心力衰竭（acute heart failure, AHF）既可以是急性起病，也可以表现为慢性心力衰竭急性失代偿 (acute decompensted heart failure, ADHF)。洋地黄类药物是既有正性肌力作用又有负性传导作用的药物，由于其独特的药理特性在心衰的治疗中得到了广泛的临床应用。但我们注意到，近些年洋地黄类药物在心衰指南中的推荐级别正在逐渐降低。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邓颖
	刘晓珺

收稿日期: 2017-12-21

作者简介: 邓颖（1967-），女，博士，主任医师，科主任

引用本文:

邓颖,刘晓珺. 如何看待洋地黄类正性肌力药在急性心力衰竭治疗中的作用及价值[J]. 中国急救医学, 2018, 38(1): 18-20.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2018.01.004 或 http://www.cnemergency.org.cn/CN/Y2018/V38/I1/18

［1］Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronicheart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC［J］. Eur J Heart Fail, 2016, 18(8):891-975. ［2］俞芝江.洋地黄药物的临床应用［J］.中级医刊,1959,616：41-42. ［3］Ziff OJ, Kotecha D. Digoxin: The good and the bad［J］. Trends in Cardiovasc Med, 2016, 26 (7): 585-595. ［4］Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure［J］. N Eng J Med, 1997, 336(8): 525-533.  ［5］Patel N, Ju C, Macon C, et al. Temporal trends of digoxin use in patients hospitalized with heart failure: analysis from the American Heart Association Get With the Guidelines-Heart Failure Registry［J］. JACC Heart Fail, 2016, 4(5):348-356. ［6］van Veldhuisen DJ, Van Gelder IC, Ahmed A, et al. Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not［J］. Eur Heart J, 2013, 34(20): 1468-1470. ［7］Stucky MA, Goldberger ZD. Digoxin: its role in contemporary medicine［J］. Postgrad Med J, 2015, 91(1079): 514-518. ［8］Adams KF Jr, Butler J, Patterson JH, et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial［J］. Eur J Heart Fail, 2016,18(8):1072-1081. ［9］Milton Packe. Why is the use of digitalis withering［J］. Eur J Heart Fail, 2017.doi:10.1002/ejhf.1043. ［10］李茂堂. 洋地黄化的概念［J］.中国乡村医生杂志, 1986, 8:34-35. ［11］佐藤友英.洋地黄疗法的进展［J］.最新医学, 1980, 1:51. ［12］朱俊. 心力衰竭的进展——（7）心功能不全：正性肌力药物的地位正在变化（续4）［J］. 中国循环杂志, 2006, 21(3): 163-164.  ［13］Muniz-Junqueira MI, Mota LM, Aires RB, et al. Digitalis inhibits and furosemide does not change the in vitro phagocytic function of neutrophilsof healthy subjects［J］.Int Immunopharmacol, 2003, 3(10-11) :1439-1445. ［14］Adams KF Jr, Ghali JK, Herbert PJ, et al. A perspective on re-evaluating digoxin′s role in the current management of patients with chronic systolic heart failure:targeting serum concentration to reduce hospitalization and improve safety profile［J］. Eur J Heart Fail, 2014, 16(5): 483-493. ［15］Mittal MK, Chockalingam P, Chockalingam A. Contemporary indications and therapeutic implications for digoxin use［J］. Am J Ther, 2011,18(4): 280-287.